The RAS oncogenes (KRAS, HRAS, NRAS) are among the most frequently mutated genes in human cancer, affecting over three million patients annually. Therapeutic development has largely focused on inhibitors for KRAS codon 12 mutations (G12C/D/V/S/R) which are key drivers in lung, colorectal, and pancreatic cancers. In contrast, mutant-selective inhibitors for Q61 variants remain elusive. A common mechanistic feature of G12…
Bronsted-basic small molecules activate GTP hydrolysis in Ras Q61 mutants
bioRxiv Cancer Biology | | Wang, Y., Chen, S., Wu, Y., Cao, Y., Shi, Z., Norinskiy, M. A., Wang, C., Celik, H., Zhang, Z.
Topics: colorectal-cancer, pancreatic-cancer, skin-cancer, blood-cancer, research